T regulatory cells, the evolution of targeted immunotherapy

S Nizar; B Meyer; C Galustian; D Kumar; A Dalgleish

doi:10.1016/j.bbcan.2010.02.001

T regulatory cells, the evolution of targeted immunotherapy

Biochim Biophys Acta. 2010 Aug;1806(1):7-17. doi: 10.1016/j.bbcan.2010.02.001. Epub 2010 Feb 23.

Authors

S Nizar¹, B Meyer, C Galustian, D Kumar, A Dalgleish

Affiliation

¹ Department of Cellular and Molecular Medicine, St George's University of London, UK.

PMID: 20188145
DOI: 10.1016/j.bbcan.2010.02.001

Abstract

T regulatory cells are able to suppress anti-tumour immunity in pre-clinical models and in patients. This review highlights the important discoveries in Treg immunology critical to the evolution of targeted immunotherapy. We also describe the therapeutic applications that are currently being assessed and their future potential.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Antigens, CD / physiology
CTLA-4 Antigen
Dendritic Cells / immunology
Forkhead Transcription Factors / physiology
Humans
Immunotherapy*
Killer Cells, Natural / immunology
Neoplasms / immunology
Neoplasms / therapy*
T-Lymphocytes, Regulatory / drug effects
T-Lymphocytes, Regulatory / physiology*

Substances

Antigens, CD
CTLA-4 Antigen
CTLA4 protein, human
FOXP3 protein, human
Forkhead Transcription Factors